ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1009

More Implementation Strategies Are Not Associated with Better Implementation Outcomes: Implementing the Lupus Patient Decision Aid

larry hearld, Jasvinder Singh and Mark Beasley, University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2023

Keywords: Health Services Research, Intervention, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 13, 2023

Title: (0993–1012) Health Services Research Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To assess the association of the number of implementation strategies for a patient lupus decision aid (DA) with perceived implementation outcomes, and the moderating effect of the organizational climate on this relationship.

Methods: We implemented a lupus patient DA across 15 U.S. rheumatology clinics made available during a regular patient clinic visit. In addition to the standardized implementation strategies provided uniformly by the research team to each site (e.g., training on DA use, designation of a clinic champion and refresher training course), each clinic could choose from a ‘menu’ of implementation strategies directed to both clinic personnel and patients, customized to their clinic. We examined the effect of the number of implementation strategies with clinic-personnel-reported implementation outcomes (acceptability, appropriateness, feasibility), and the extent of impact of the organizational climate (e.g., learning environment, readiness for change) on this relationship.

Results: At the 4-month post-implementation period, the average perceptions of the lupus DA were as follows: acceptability, 3.49; appropriateness, 3.37; and feasibility, 3.40. The mean number of total strategies implemented by the participating clinics was 3.37, with 2.07 clinic-focused strategies and 1.29 patient focused strategies, that remained stable during follow-up. Adjusted for clinic and clinic personnel characteristics, and time since implementation, we found the following associations for implementation strategies: (1) total strategies not significantly associated with lupus DA acceptability, appropriateness, feasibility, success, or permanence; (2) the number of clinic-focused strategies associated positively and significantly with lupus DA acceptability, appropriateness, and feasibility; and (c) the number of patient-focused strategies was negatively significantly associated with lupus DA acceptability and feasibility but not appropriateness. We found significant moderation of the relationship between implementation strategies and implementation outcomes by the learning environment and readiness for change.

Conclusion: We found that the overall number of implementation strategies was not associated with perceptions of DA acceptability, appropriateness, and feasibility; however, these relationships did differ for different implementation targets and under different organizational conditions. Our findings highlight the importance of the context but suggest that a very nuanced consideration of contextual characteristics is needed as aggregated factors such as organizational readiness for change and its learning climate contribute to implementation success in different ways and for different implementation outcomes.


Disclosures: l. hearld: None; J. Singh: Other, 2, 6, 11, 11, 12, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix, Charlotte’s Web, 12, Atai life sciences, kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, 12, speaker’s bureau of Simply Speaking, other, 12, received institutional research support from Zimmer Biomet Holdings. JAS received food and beverage payments from Intuitive Surgical Inc./Philips Elec, Other, 12, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam; M. Beasley: None.

To cite this abstract in AMA style:

hearld l, Singh J, Beasley M. More Implementation Strategies Are Not Associated with Better Implementation Outcomes: Implementing the Lupus Patient Decision Aid [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/more-implementation-strategies-are-not-associated-with-better-implementation-outcomes-implementing-the-lupus-patient-decision-aid/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/more-implementation-strategies-are-not-associated-with-better-implementation-outcomes-implementing-the-lupus-patient-decision-aid/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology